The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy
Open accessAbstract
Cholangiocarcinomas are devastating cancers that are increasing in both their worldwide incidence and mortality rates. The challenges posed by these often lethal biliary tract cancers are daunting, with conventional treatment options being limited and the only hope for long-term survival being that of complete surgical resection of the tumor. Unfortunately, the vast majority of patients with cholangiocarcinoma typically seek treatment with advanced disease, and often these patients are deemed poor candidates for curative surgery. Moreover, conventional chemotherapy and radiation therapy have not been shown to be effective in prolonging long-term survival, and although photodynamic therapy combined with stenting has been reported to be effective as a palliative treatment, it is not curative. Thus, there is a real need to develop novel chemopreventive and adjuvant therapeutic strategies for cholangiocarcinoma based on exploiting select molecular targets that would impact in a significant way on clinical outcome. This review focuses on potential preventive targets in cholangiocarcinogenesis, such as inducible nitric oxide synthase, cyclooxygenase-2, and altered bile acid signaling pathways. In addition, molecular alterations related to dysregulation of cholangiocarcinoma cell growth and survival, aberrant gene expression, invasion and metastasis, and tumor microenvironment are described in the context of various clinical and pathological presentations. Moreover, an emphasis is placed on the importance of critical signaling pathways and postulated interactions, including those of ErbB-2, hepatocyte growth factor/Met, interleukin-6/glycoprotein130, cyclooxygenase-2, vascular endothelial growth factor, transforming growth factor-β, MUC1 and MUC4, β-catenin, telomerase, and Fas pathways as potential molecular therapeutic targets in cholangiocarcinoma. cholangiocarcinoma. (Hepatology 2005;41:5-15.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002) · Nature Medicine · doi:10.1038/nm0302-289 · Cited by 836
Jaiswal, M., LaRusso, N. F., Burgart, L. J., & Gores, G. J. (2000) · PubMed · Cited by 653
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study
Ortner, M. E. J., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., Voderholzer, W., Schachschal, G., Mössner, J., & Lochs, H. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.015 · Cited by 608
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
Khan, S. A., Taylor-Robinson, S. D., Toledano, M. B., Beck, A., Elliott, P., & Thomas, H. C. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00297-0 · Cited by 570
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998
Taylor-Robinson, S. D., Toledano, M. B., Arora, S., Keegan, T. J., Hargreaves, S., Beck, A., Khan, S. A., Elliott, P., & Thomas, H. C. (2001) · Gut · doi:10.1136/gut.48.6.816 · Cited by 381
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Easwaran, V., Lee, S. H., Inge, L. J., Guo, L., Goldbeck, C., Garrett, E. N., Wiesmann, M., García, P. D., Fuller, J. H., Chan, V. W.-F., et al. (2003) · PubMed · Cited by 334
Cited by
Liver Fluke Induces Cholangiocarcinoma
Sripa, B., Kaewkes, S., Sithithaworn, P., Mairiang, E., Laha, T., Smout, M., Pairojkul, C., Bhudhisawasdi, V., Tesana, S., Thinkamrop, B., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040201 · Cited by 775
Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities
Mocellin, S., Bronte, V., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20092 · Cited by 478
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604129 · Cited by 404
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 318
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009
Aljiffry, M., Walsh, M. J., & Molinari, M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4240 · Cited by 286
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H.-J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Fevery, J., Verslype, C., Lai, G., Aerts, R., & Van Steenbergen, W. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9681-4 · Cited by 145
Metadata
- Authors
- Sirica, A. E.
- Venue
- Hepatology
- Published
- 2005-01
- Volume
- 41
- Issue
- 1
- Pages
- 5-15
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2054566387
- Cited by
- 315
- References
- 96
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.